Kura Oncology (FRA:KUR) Cyclically Adjusted Book per Share: €4.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KUR Kura Oncology Inc FRA:KUR
36 GF Score
Price €9.84
! 7 Warning Signs
View Full Analysis

What is Kura Oncology Cyclically Adjusted Book per Share?

Kura Oncology FRA:KUR -5.38% 36 Cyclically Adjusted Book per Share is €4.83 as of Mar. 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Kura Oncology's adjusted book value per share for the three months ended in Mar. 2026 was €1.051. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.83 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kura Oncology's average Cyclically Adjusted Book Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-14), Kura Oncology's current stock price is €9.84. Kura Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €4.83. Kura Oncology's Cyclically Adjusted PB Ratio of today is 2.04.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Kura Oncology was 2.03. The lowest was 0.93. And the median was 1.41.


Kura Oncology  (FRA:KUR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kura Oncology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.84/4.83
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Kura Oncology was 2.03. The lowest was 0.93. And the median was 1.41.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Kura Oncology Cyclically Adjusted Book per Share Related Terms


Kura Oncology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Kura Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology Cyclically Adjusted Book per Share Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 5.56 4.95

Kura Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.74 5.15 5.09 4.95 4.83

FRA:KUR vs REPL, AVTX, SANA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Kura Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Cyclically Adjusted PB Ratio falls into.


FRA:KUR
36GF Score
Kura Oncology Inc FRA:KUR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kura Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.051/330.2130*330.2130
=1.051

Current CPI (Mar. 2026) = 330.2130.

Kura Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.917 241.018 3.997
201609 2.655 241.428 3.631
201612 2.523 241.432 3.451
201703 2.197 243.801 2.976
201706 1.817 244.955 2.449
201709 2.477 246.819 3.314
201712 2.233 246.524 2.991
201803 3.035 249.554 4.016
201806 2.883 251.989 3.778
201809 3.936 252.439 5.149
201812 3.709 251.233 4.875
201903 3.468 254.202 4.505
201906 4.829 256.143 6.225
201909 4.682 256.759 6.021
201912 4.339 256.974 5.576
202003 4.048 258.115 5.179
202006 5.092 257.797 6.522
202009 4.595 260.280 5.830
202012 7.586 260.474 9.617
202103 7.428 264.877 9.260
202106 6.993 271.696 8.499
202109 6.822 274.310 8.212
202112 6.735 278.802 7.977
202203 6.490 287.504 7.454
202206 6.362 296.311 7.090
202209 6.336 296.808 7.049
202212 5.808 296.797 6.462
202303 5.393 301.836 5.900
202306 5.722 305.109 6.193
202309 5.426 307.789 5.821
202312 4.900 306.746 5.275
202403 6.100 312.332 6.449
202406 5.666 314.175 5.955
202409 4.911 315.301 5.143
202412 5.050 315.605 5.284
202503 4.173 319.799 4.309
202506 3.051 322.561 3.123
202509 2.375 324.800 2.415
202512 1.693 324.054 1.725
202603 1.051 330.213 1.051

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €4.83 mean?
Kura Oncology (FRA:KUR) has a Cyclically Adjusted Book per Share of €4.83 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kura Oncology and its competitors.
Is Kura Oncology's Cyclically Adjusted Book per Share too high?
Kura Oncology's current Cyclically Adjusted Book per Share is €4.83. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Cyclically Adjusted Book per Share compare to REPL and AVTX?
Kura Oncology's Cyclically Adjusted Book per Share of €4.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kura Oncology and its competitors. Kura Oncology's current Cyclically Adjusted Book per Share is €4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current Cyclically Adjusted Book per Share of €4.83. The current Cyclically Adjusted Book per Share is €4.83. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current Cyclically Adjusted Book per Share is €4.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KURA:USA
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score

Get the complete analysis for FRA:KUR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.84
Price